The IL-7R signaling specifically regulates effector but not regulatory T cell homing to the gut by controlling alpha4 and beta7 integrin expression, thereby implicating blockade of the IL-7R as a novel therapeutic option in IBD (143). Here, IL7R is linked to inflammatory bowel disease.